ATM and non-small cell lung carcinoma: In conclusion, we performed comprehensive genomic analysis to investigate the molecular and clinical significance of ATM/ATR pathogenic mutations in NSCLC, and we found ATM/ATR-mutated patients have a unique mutational profile and a specific enrichment of FA/HR aberrations, which might result in elevated nucleotide-level changes and poor prognosis.